Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

E.E.W. Cohen; D. Soulières; C. Le Tourneau; J. Dinis; L. Licitra; M.-J. Ahn; A. Soria; J.-P. Machiels; N. Mach; R. Mehra; B. Burtness; P. Zhang; J. Cheng; R.F. Swaby; K.J. Harrington; M. Acosta-Rivera; D.R. Adkins; M. Aghmesheh; M. Airoldi; E. Aleknavicius; Y. Al-Farhat; A.P. Algazi; S. Almokadem; A. Alyasova; J.R. Bauman; M. Benasso; A. Berrocal; V. Bray; B.A. Burtness; F. Caponigro; A. Castro; T.P. Cescon; K. Chan; A. Chaudhry; B. Chauffert; E. Cohen; T. Csoszi; J.P. De Boer; J.-P. Delord; A. Dietz; C. Dupuis; L. Digue; J. Erfan; Y. Escobar Alvarez; M. Evans; M.J. Fidler; M.D. Forster; S. Friesland; A.K. Ganti; A. Russo

doi:10.1016/S0140-6736(18)31999-8

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

E.E.W. Cohen, D. Soulières, C. Le Tourneau, J. Dinis, L. Licitra, M.-J. Ahn, A. Soria, J.-P. Machiels, N. Mach, R. Mehra, B. Burtness, P. Zhang, J. Cheng, R.F. Swaby, K.J. Harrington, M. Acosta-Rivera, D.R. Adkins, M. Aghmesheh, M. Airoldi, E. AleknaviciusY. Al-Farhat, A.P. Algazi, S. Almokadem, A. Alyasova, J.R. Bauman, M. Benasso, A. Berrocal, V. Bray, B.A. Burtness, F. Caponigro, A. Castro, T.P. Cescon, K. Chan, A. Chaudhry, B. Chauffert, E. Cohen, T. Csoszi, J.P. De Boer, J.-P. Delord, A. Dietz, C. Dupuis, L. Digue, J. Erfan, Y. Escobar Alvarez, M. Evans, M.J. Fidler, M.D. Forster, S. Friesland, A.K. Ganti, A. Russo

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	156-167
Number of pages	12
Journal	The Lancet
Volume	393
Issue number	10167
DOIs	https://doi.org/10.1016/S0140-6736(18)31999-8
Publication status	Published - 2019

Access to Document

10.1016/S0140-6736(18)31999-8

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059907778&doi=10.1016%2fS0140-6736%2818%2931999-8&partnerID=40&md5=91c2715689ba18e96712cf192281df89

Cite this

Cohen, E. E. W., Soulières, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M-J., Soria, A., Machiels, J-P., Mach, N., Mehra, R., Burtness, B., Zhang, P., Cheng, J., Swaby, R. F., Harrington, K. J., Acosta-Rivera, M., Adkins, D. R., Aghmesheh, M., Airoldi, M., ... Russo, A. (2019). Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet, 393(10167), 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. / Cohen, E.E.W.; Soulières, D.; Le Tourneau, C.; Dinis, J.; Licitra, L.; Ahn, M.-J.; Soria, A.; Machiels, J.-P.; Mach, N.; Mehra, R.; Burtness, B.; Zhang, P.; Cheng, J.; Swaby, R.F.; Harrington, K.J.; Acosta-Rivera, M.; Adkins, D.R.; Aghmesheh, M.; Airoldi, M.; Aleknavicius, E.; Al-Farhat, Y.; Algazi, A.P.; Almokadem, S.; Alyasova, A.; Bauman, J.R.; Benasso, M.; Berrocal, A.; Bray, V.; Burtness, B.A.; Caponigro, F.; Castro, A.; Cescon, T.P.; Chan, K.; Chaudhry, A.; Chauffert, B.; Cohen, E.; Csoszi, T.; De Boer, J.P.; Delord, J.-P.; Dietz, A.; Dupuis, C.; Digue, L.; Erfan, J.; Escobar Alvarez, Y.; Evans, M.; Fidler, M.J.; Forster, M.D.; Friesland, S.; Ganti, A.K.; Russo, A.

In: The Lancet, Vol. 393, No. 10167, 2019, p. 156-167.

Research output: Contribution to journal › Article › peer-review

Cohen, EEW, Soulières, D, Le Tourneau, C, Dinis, J, Licitra, L, Ahn, M-J, Soria, A, Machiels, J-P, Mach, N, Mehra, R, Burtness, B, Zhang, P, Cheng, J, Swaby, RF, Harrington, KJ, Acosta-Rivera, M, Adkins, DR, Aghmesheh, M, Airoldi, M, Aleknavicius, E, Al-Farhat, Y, Algazi, AP, Almokadem, S, Alyasova, A, Bauman, JR, Benasso, M, Berrocal, A, Bray, V, Burtness, BA, Caponigro, F, Castro, A, Cescon, TP, Chan, K, Chaudhry, A, Chauffert, B, Cohen, E, Csoszi, T, De Boer, JP, Delord, J-P, Dietz, A, Dupuis, C, Digue, L, Erfan, J, Escobar Alvarez, Y, Evans, M, Fidler, MJ, Forster, MD, Friesland, S, Ganti, AK & Russo, A 2019, 'Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study', The Lancet, vol. 393, no. 10167, pp. 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8

Cohen, E.E.W. ; Soulières, D. ; Le Tourneau, C. ; Dinis, J. ; Licitra, L. ; Ahn, M.-J. ; Soria, A. ; Machiels, J.-P. ; Mach, N. ; Mehra, R. ; Burtness, B. ; Zhang, P. ; Cheng, J. ; Swaby, R.F. ; Harrington, K.J. ; Acosta-Rivera, M. ; Adkins, D.R. ; Aghmesheh, M. ; Airoldi, M. ; Aleknavicius, E. ; Al-Farhat, Y. ; Algazi, A.P. ; Almokadem, S. ; Alyasova, A. ; Bauman, J.R. ; Benasso, M. ; Berrocal, A. ; Bray, V. ; Burtness, B.A. ; Caponigro, F. ; Castro, A. ; Cescon, T.P. ; Chan, K. ; Chaudhry, A. ; Chauffert, B. ; Cohen, E. ; Csoszi, T. ; De Boer, J.P. ; Delord, J.-P. ; Dietz, A. ; Dupuis, C. ; Digue, L. ; Erfan, J. ; Escobar Alvarez, Y. ; Evans, M. ; Fidler, M.J. ; Forster, M.D. ; Friesland, S. ; Ganti, A.K. ; Russo, A. / Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. In: The Lancet. 2019 ; Vol. 393, No. 10167. pp. 156-167.

@article{8bc9fa9af5d54f66a6925e87575af802,

title = "Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study",

author = "E.E.W. Cohen and D. Souli{\`e}res and {Le Tourneau}, C. and J. Dinis and L. Licitra and M.-J. Ahn and A. Soria and J.-P. Machiels and N. Mach and R. Mehra and B. Burtness and P. Zhang and J. Cheng and R.F. Swaby and K.J. Harrington and M. Acosta-Rivera and D.R. Adkins and M. Aghmesheh and M. Airoldi and E. Aleknavicius and Y. Al-Farhat and A.P. Algazi and S. Almokadem and A. Alyasova and J.R. Bauman and M. Benasso and A. Berrocal and V. Bray and B.A. Burtness and F. Caponigro and A. Castro and T.P. Cescon and K. Chan and A. Chaudhry and B. Chauffert and E. Cohen and T. Csoszi and {De Boer}, J.P. and J.-P. Delord and A. Dietz and C. Dupuis and L. Digue and J. Erfan and {Escobar Alvarez}, Y. and M. Evans and M.J. Fidler and M.D. Forster and S. Friesland and A.K. Ganti and A. Russo",

note = "Cited By :117 Export Date: 12 February 2020",

year = "2019",

doi = "10.1016/S0140-6736(18)31999-8",

language = "English",

volume = "393",

pages = "156--167",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet Publishing Group",

number = "10167",

}

TY - JOUR

T1 - Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

AU - Cohen, E.E.W.

AU - Soulières, D.

AU - Le Tourneau, C.

AU - Dinis, J.

AU - Licitra, L.

AU - Ahn, M.-J.

AU - Soria, A.

AU - Machiels, J.-P.

AU - Mach, N.

AU - Mehra, R.

AU - Burtness, B.

AU - Zhang, P.

AU - Cheng, J.

AU - Swaby, R.F.

AU - Harrington, K.J.

AU - Acosta-Rivera, M.

AU - Adkins, D.R.

AU - Aghmesheh, M.

AU - Airoldi, M.

AU - Aleknavicius, E.

AU - Al-Farhat, Y.

AU - Algazi, A.P.

AU - Almokadem, S.

AU - Alyasova, A.

AU - Bauman, J.R.

AU - Benasso, M.

AU - Berrocal, A.

AU - Bray, V.

AU - Burtness, B.A.

AU - Caponigro, F.

AU - Castro, A.

AU - Cescon, T.P.

AU - Chan, K.

AU - Chaudhry, A.

AU - Chauffert, B.

AU - Cohen, E.

AU - Csoszi, T.

AU - De Boer, J.P.

AU - Delord, J.-P.

AU - Dietz, A.

AU - Dupuis, C.

AU - Digue, L.

AU - Erfan, J.

AU - Escobar Alvarez, Y.

AU - Evans, M.

AU - Fidler, M.J.

AU - Forster, M.D.

AU - Friesland, S.

AU - Ganti, A.K.

AU - Russo, A.

N1 - Cited By :117 Export Date: 12 February 2020

PY - 2019

Y1 - 2019

U2 - 10.1016/S0140-6736(18)31999-8

DO - 10.1016/S0140-6736(18)31999-8

M3 - Article

VL - 393

SP - 156

EP - 167

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10167

ER -